Will we see you in Boston for CTAD 2023? Schedule a time to chat with a member of our team during the show to learn about our site network’s decades of experience with Alzheimer’s disease trials and recruiting, enrolling, and retaining inclusive, diverse populations.
Reach out to a team member to schedule a meeting:
- Chris Cugliari, Vice President of Corporate Development, Headlands Research
- McKenzie Lang, Director, Business Development, Headlands Research
- Sharon Cohen, Medical Director and Principal Investigator, Toronto Memory Program
In addition, attend the following late-breaking oral communications of research involving our sites:
Wednesday, October 25
11:05am
LB10 - Phase 1 safety, tolerability, and pharmacological results of ALN-APP, the first investigational RNA
Co-authored by: Sharon Cohen, Medical Director and Principal Investigator, Toronto Memory Program
5:10 p.m.
LB12 - Reduced caregiver distress associated with neuropsychiatric symptoms in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer’s disease
Co-authored by: Sharon Cohen, Medical Director and Principal Investigator, Toronto Memory Program
Thursday, October 26
10:15 a.m.
LB16 - Progression analysis on cognitive, functional, and behavioral endpoints in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer’s disease
Co-authored by: Sharon Cohen, Medical Director and Principal Investigator, Toronto Memory Program
Friday, October 27
3:30 p.m.
LB23 - Results of a Phase 2 randomized withdrawal study of simufilam in mild-to-moderate Alzheimer’s
Co-authored by: Ian Cohen, President and Research Investigator, Toronto Memory Program
View the poster presentations of research involving our sites:
LP030 Cerebral Amyloid Angiopathy and Comorbid Cardiovascular Risk Factors in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Results from APOLLOE4 Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801
Co-authored by: Sharon Cohen, Medical Director and Principal Investigator, Toronto Memory Program
LP072 Implementing cognitive assessment and RetiSpec retinal screening in community-based settings: Enhancing early detection of Alzheimer’s disease
Co-authored by: Sharon Cohen, Medical Director and Principal Investigator; Amelia Hansen, Nurse Practioner; and Michelle Martinez, Clinic Manager at Toronto Memory Program